CNTX Context Therapeutics Inc
Company Analysis
Latest News
🔴 Context Therapeutics is trading 6.97% down in pre-market with no confirmed company-specific catalyst identified
Context Therapeutics is trading 6.97% down at $0.48, with no company-specific announcement or confirmed overnight catalyst identified for August 21, 2026. -...
🟢 Context Therapeutics is trading 5% up today amid trading volatility
Context Therapeutics is trading 5.13% up at $0.51, with the gain appearing to reflect trading volatility rather than a confirmed fundamental catalyst. - No...
🔴 Context Therapeutics is trading 6.73% down today as the specific cause remains unclear
Context Therapeutics is trading 6.73% down now at $0.46, with the specific cause unclear and no confirmed company-specific announcement dated August 19,...
🔴 Context Therapeutics is trading 5.26% down today as Nasdaq Composite falls 1.32%
Context Therapeutics is trading 5.26% down at $0.50 amid broader market weakness, with the Nasdaq Composite down 1.32% and the S&P 500 down 0.58%. - No fresh...
🟢 Context Therapeutics is trading 5% up today — no confirmed catalyst identified
Context Therapeutics is trading 5.17% up now at $0.53 on August 14, 2026, with no new company-specific announcement, filing, earnings release, or analyst...
🟢 Context Therapeutics is trading 5.1% up today on softer PPI and lower Fed hike expectations
Context Therapeutics is trading at $0.49, up +5.11% on August 13, 2026, as softer-than-expected July PPI and slightly higher jobless claims reduced...
🔴 Context Therapeutics is trading 8% down today after Q2 EPS miss and CT-95 discontinuation
Context Therapeutics is trading 8% down now at $0.45 after investors continued reassessing its August 5 second-quarter report. - The company posted a $14.6...
Context Therapeutics Drops 18.5% After Hours: Is the CTIM-76 Hype Trade Running Out of Steam?
Shares of Context Therapeutics slid to $0.56 in after-hours trading Thursday, erasing a chunk of the gains from a rally that had lifted the micro-cap biotech...
🔴 Context Therapeutics is trading 25% down today after $14.6 million Q2 net loss
Context Therapeutics is trading 25% down at $0.52 after reporting a $14.6 million second-quarter net loss and missing consensus EPS estimates by $0.05. -...
🔴 Context Therapeutics Plunges 22.1% in Premarket on Wider Q2 Loss, EPS Miss, and Pipeline Prioritization
Context Therapeutics is trading 22.1% down at $0.54 in pre-market, extending a sharp after-hours selloff after reporting its Q2 2026 financial results. The...
🔴 Context Therapeutics is trading 24.2% down today ahead of Q2 earnings release
Context Therapeutics is trading 24.2% down at $0.53 in after-hours trading as investors position ahead of the company’s upcoming quarterly financial...
🔴 Context Therapeutics drops in after-hours trading ahead of Q2 earnings
Context Therapeutics is trading at $0.56 (down approx. 18.8% from its daily close of $0.69) in after-hours as investors react to upcoming Q2 2026 earnings. * ...
🔴 Context Therapeutics is trading 6.3% down today as investors take profits ahead of Q2 earnings and clinical updates
Context Therapeutics is trading at $0.65 (6.3% down) in after-hours trading following a strong regular session driven by anticipation of its Q2 2026 earnings...
🟢 Context Therapeutics is trading 6.1% up today ahead of Q2 earnings and clinical updates
Context Therapeutics is trading at $0.66 (+6.11%) as investors position ahead of the company’s Q2 2026 earnings report and monitor clinical progress for...
🟢 Context Therapeutics is trading 5.4% up today on Q2 earnings optimism and clinical progress
Context Therapeutics is trading 5.4% up at $0.64 as investors position ahead of the company’s Q2 2026 earnings report and monitor clinical progress for...
Context Therapeutics Inc Q2 2026 Earnings Preview: What Analysts Expect on August 05, 2026
Context Therapeutics is expected to report a consensus EPS of -$0.10 on zero revenue for the second quarter, with the current stock price of $0.62 reflecting...
🟢 Context Therapeutics is trading 5% up today amid broader market strength
Context Therapeutics is trading 5% up at $0.63, rebounding modestly from recent weakness as the broader market shows a risk-on tone. • The move appears...
🔴 Context Therapeutics is trading 5.1% down today amid broader market weakness and thin liquidity
Context Therapeutics is trading at $0.59 (5.1% down) in after-hours trading as broader market weakness and thin liquidity weigh on the small-cap biotech. •...
🔴 Context Therapeutics is trading 5% down today on profit-taking after recent strength
Context Therapeutics is trading 5% down at $0.59 today, giving back a portion of last week’s biotech-driven gains. • No new company-specific filings, clinical...
🟢 Context Therapeutics rises 5.2% — Biotech Sector Rallies on Blockbuster M&A Deal and Positive Trial Data
With Biotech (XBI) up 2.3%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector is experiencing a significant...